HSBC Holdings plc reiterated their reduce rating on shares of AstraZeneca plc (LON:AZN) in a research note published on Monday, Marketbeat Ratings reports. They currently have a GBX 4,100 ($52.95) price target on the biopharmaceutical company’s stock.
A number of other research firms also recently issued reports on AZN. Morgan Stanley restated an overweight rating and issued a GBX 5,600 ($72.32) price target on shares of AstraZeneca plc in a research report on Friday, June 23rd. UBS AG set a GBX 5,150 ($66.51) price target on shares of AstraZeneca plc and gave the stock a neutral rating in a research report on Tuesday, June 27th. Shore Capital restated a hold rating on shares of AstraZeneca plc in a research report on Wednesday, June 21st. Barclays PLC restated an overweight rating and issued a GBX 6,000 ($77.49) price target on shares of AstraZeneca plc in a research report on Monday, June 5th. Finally, J P Morgan Chase & Co restated a neutral rating on shares of AstraZeneca plc in a research report on Monday, June 5th. Three equities research analysts have rated the stock with a sell rating, ten have given a hold rating and nine have given a buy rating to the stock. AstraZeneca plc presently has a consensus rating of Hold and an average target price of GBX 5,022.91 ($64.87).
AstraZeneca plc (AZN) opened at 4806.00 on Monday. AstraZeneca plc has a 1-year low of GBX 3,996.00 and a 1-year high of GBX 5,520.00. The firm’s market capitalization is GBX 60.84 billion. The firm has a 50-day moving average of GBX 4,566.78 and a 200-day moving average of GBX 4,881.73.
COPYRIGHT VIOLATION WARNING: “AstraZeneca plc (AZN) Receives “Reduce” Rating from HSBC Holdings plc” was reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this story on another publication, it was stolen and republished in violation of international copyright legislation. The correct version of this story can be viewed at https://www.chaffeybreeze.com/2017/09/15/astrazeneca-plc-azn-receives-reduce-rating-from-hsbc-holdings-plc.html.
The business also recently announced a dividend, which was paid on Monday, September 11th. Investors of record on Thursday, August 10th were given a dividend of GBX 68.90 ($0.89) per share. This represents a yield of 1.35%. The ex-dividend date of this dividend was Thursday, August 10th.
In other AstraZeneca plc news, insider Nazneen Rahman purchased 39 shares of the stock in a transaction on Thursday, July 27th. The shares were purchased at an average price of GBX 4,370 ($56.44) per share, with a total value of £1,704.30 ($2,201.08).
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.